Last reviewed · How we verify

NCT03678090

The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.

Withdrawn Phase 2 Last updated 5 March 2020
What this trial tests

Phase 2 trial testing tPA standard dosage in Pleural Effusion. Withdrawn.

Timeline
1 December 2018
Primary endpoint
28 February 2020
28 February 2020

Quick facts

Lead sponsorYale University
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date1 December 2018
Primary completion28 February 2020
Estimated completion28 February 2020

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

18 and older, any sex, with Pleural Effusion or Cancer, Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The safety and efficacy of fibrinolysis in patients with an indwelling pleural catheter for multi-loculated malignant pleural effusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pleural Effusion

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03678090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing